Matrai Gyogyintezet

Gyöngyös 7151

4 studies enrolling now · 6 studies all time

What they study most

Advanced Non-Small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive, Extensive Stage Small-cell Lung Cancer, Extensive-Stage Small-Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Non-small Cell Lung Cancer, Small Cell Lung Cancer (SCLC), Small-Cell Lung Cancer, Small-cell Lung Cancer

Studies at this site

• A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) — Recruiting now
• Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 — Recruiting now
• Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC — Recruiting now
• A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) — Recruiting now
• Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer — Running, not enrolling
• Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab — Running, not enrolling